Parallel phase 1 clinical trials in the US and in China:accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance  

作　　者：Xiao Xu 

机构地区：[1]ACEA Biosciences Inc [2]ACEA Pharmaceutical Research

出　　处：《Chinese Journal of Cancer》2015年第7期285-287,共3页

基　　金：supported by China State Twelfth Five-Year Plan Key Project(No.2013ZX09401003);Hangzhou Municipal Key Project(No.2014-1249)

摘　　要：Avitinib,a new generation inhibitor of epidermal growth factor receptor(EGFR),was approved for clinical trial in both China and the United States,and the phase 1 trials were initiated in both countries in parallel.In the preclinical studies,avitinib showed three novel features including(1)irreversibly binding EGFR by forming a covalent bound with Cys797 in the ATP-binding pocket,(2) sparing wild-type EGFR,and(3)overcoming T790M-induced resistance.Avitinib is the first China-developed novel EGFR inhibitor that has entered in global clinical trials,and will provide a precision targeted therapy for non-small cell lung cancer patients.Avitinib,a new generation inhibitor of epidermal growth factor receptor（EGFR）,was approved for clinical trial in both China and the United States,and the phase 1 trials were initiated in both countries in parallel.In the preclinical studies,avitinib showed three novel features including（1）irreversibly binding EGFR by forming a covalent bound with Cys797 in the ATP-binding pocket,（2） sparing wild-type EGFR,and（3）overcoming T790M-induced resistance.Avitinib is the first China-developed novel EGFR inhibitor that has entered in global clinical trials,and will provide a precision targeted therapy for non-small cell lung cancer patients.

关 键 词：非小细胞肺癌 EGFR 临床试验 诱导抗性 抑制剂 突变 中国 美国 

分 类 号：R734.2[医药卫生—肿瘤]